NCT05783934Completed
Demyelination and Remyelination in Multiple Sclerosis (MS) Detected by Brain Amyloid PET-CT
Evaluation of the Degree of Demyelination and Remyelination in Multiple Sclerosis (MS) Detected by Brain Positron Emission Tomography With Amyloid Markers (PET-CT 18F-Florbetaben) and Comparison With MRI Findings
Source: ClinicalTrials.gov · Last updated 30 May 2025
Brief summary (registry, in English)
The goal of this clinical trial study is to evaluate the presence of relationships between PET and MRI images indicative of chronic inflammatory activity (smoldering plaques), apparent absence of inflammatory activity (silent plaques without microglial rim), or indicative of more recent inflammatory activity, in contrast-enhanced areas or in T2/Flair-positive areas of not distant onset in patients diagnosed with progressive (secondary or primary) stage multiple sclerosis and in patients in relapse and remission. Laboratory analysis of serum markers will be performed: neuronal and glial cytoskeletal proteins (e.g., Nf-L, pN-FH, GFAP), and the levels of neurotrophic factors (e.g., BDNF, GDNF) and cytokines (e.g., TNFα, IL-6, IL-1β, interferon) will be evaluated.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 6 (actual)
- First submitted
- 13 Mar 2023
- Start date
- 27 Jul 2021
- Primary completion date
- 15 Nov 2023
- Lead sponsor
- Istituti Clinici Scientifici Maugeri SpA
- Diseases
- Multiple sclerosis
- NCT number
- NCT05783934
What you commit to
- Study type: Interventional
- Participants enrolled: 6
- From 27 Jul 2021 to the primary completion date, 15 Nov 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- patients with a cognitive impairment interfering with full study participation (Minimental score less than 24)
Other
- a disability greater than 7
- patients with internal medical problems that in the opinion of the investigator may interfere with full participation and collaboration
- inability to undergo MRI or PET examinations
- ongoing pregnancy and lactation
Who the study is looking for
- progressive stage of multiple sclerosis (both secondary and primary, SMP)
- patients in relapsing-remitting multiple sclerosis (RRMS)
Age in the registry: 18 years to 99 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| ICS Maugeri SpA SB IRCCS Coordinator of this site? Confirm its status | Pavia | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.